1,070,263 Cellebrite DI Ltd. $CLBT Shares Sold by Phoenix Financial Ltd.

Phoenix Financial Ltd. decreased its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 17.3% during the 3rd quarter, Holdings Channel.com reports. The fund owned 5,111,006 shares of the company’s stock after selling 1,070,263 shares during the period. Phoenix Financial Ltd.’s holdings in Cellebrite DI were worth $57,553,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Nine Ten Capital Management LLC lifted its holdings in Cellebrite DI by 19.8% in the second quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company’s stock worth $60,251,000 after acquiring an additional 682,933 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Cellebrite DI by 93.7% during the second quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company’s stock valued at $44,529,000 after purchasing an additional 1,475,579 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Cellebrite DI by 14.7% during the first quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company’s stock valued at $39,420,000 after purchasing an additional 365,700 shares during the last quarter. Principal Financial Group Inc. grew its holdings in shares of Cellebrite DI by 33.9% during the first quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company’s stock valued at $29,712,000 after purchasing an additional 545,334 shares during the last quarter. Finally, Weiss Asset Management LP raised its position in shares of Cellebrite DI by 3,485.3% during the 1st quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock worth $26,180,000 after purchasing an additional 1,846,851 shares during the period. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Trading Up 5.9%

NASDAQ:CLBT traded up $0.64 during mid-day trading on Friday, hitting $11.53. The stock had a trading volume of 5,109,359 shares, compared to its average volume of 1,881,015. The stock has a market capitalization of $2.88 billion, a price-to-earnings ratio of 48.04, a P/E/G ratio of 1.67 and a beta of 1.06. The company has a 50 day simple moving average of $11.60 and a 200-day simple moving average of $13.22. Cellebrite DI Ltd. has a 52 week low of $9.58 and a 52 week high of $19.39.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Thursday, November 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.08. Cellebrite DI had a net margin of 12.14% and a return on equity of 17.47%. The firm had revenue of $149.02 million during the quarter, compared to analyst estimates of $145.83 million. As a group, equities research analysts anticipate that Cellebrite DI Ltd. will post 0.37 earnings per share for the current year.

Insiders Place Their Bets

In other news, CRO Marcus Jewell sold 12,562 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $11.24, for a total transaction of $141,196.88. Following the completion of the transaction, the executive directly owned 427,128 shares in the company, valued at approximately $4,800,918.72. The trade was a 2.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CMO David Gee sold 4,323 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $11.36, for a total value of $49,109.28. Following the completion of the transaction, the chief marketing officer directly owned 135,281 shares of the company’s stock, valued at $1,536,792.16. This trade represents a 3.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 57,143 shares of company stock worth $645,005. 5.70% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Cellebrite DI

Investors following CLBT have been watching these headlines:

• Positive Sentiment: Cellebrite reported Q3 revenue of $149.0 million, above the cited consensus estimate of $145.8 million, and EPS of $0.17. The company also reported 20% ARR growth, a 31% trailing-twelve-month free-cash-flow margin, and $26.7 million in net income. Cellebrite Q3 results
• Positive Sentiment: JPMorgan lowered its target from $16 to $15 but kept its Overweight rating, indicating continued optimism despite a more cautious valuation. JPMorgan analyst ratings
• Negative Sentiment: Q4 2026 revenue guidance of $145 million–$150 million fell short of the $151.6 million consensus estimate, raising a near-term concern. Full-year revenue guidance of $553 million–$558 million was broadly in line with the $556.8 million estimate.

Wall Street Analyst Weigh In

CLBT has been the topic of several recent research reports. DA Davidson reissued a “buy” rating and issued a $15.00 price target on shares of Cellebrite DI in a report on Tuesday, September 15th. Needham & Company LLC boosted their price objective on Cellebrite DI from $12.50 to $14.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings downgraded Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, August 27th. JPMorgan Chase & Co. dropped their target price on Cellebrite DI from $16.00 to $15.00 and set an “overweight” rating on the stock in a research report on Friday. Finally, Lake Street Capital dropped their target price on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $14.75.

About Cellebrite DI

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.